Given their consistent down-regulation, and the fact that FADS2 was found down-regulated after combinational treatment of selinexor and carfilzomib (Fig. 3d), we tested whether FADS2 and HERC4 play a role in carfilzomib’s anti-cancer effects. Here, FADS2 is linked to cancer.